MammoScreen
Breast Cancer Detection
ApprovedActive
Key Facts
About Therapixel
Therapixel is a private, commercial-stage French medtech company focused on AI for radiology. It has successfully transitioned from its origins in surgical imaging software to become a pure-play radiology AI developer, with MammoScreen as its cornerstone product. The company has achieved significant commercial validation, including a partnership with Mayo Clinic and a national deployment deal with Onsite Women's Health. Its strategy is centered on leveraging its award-winning AI algorithms to improve the accuracy and efficiency of breast cancer screening.
View full company profileOther Breast Cancer Detection Drugs
| Drug | Company | Phase |
|---|---|---|
| MVT-501 | Microvascular Therapeutics | Pre-clinical |
| Breast Cancer Early Detection Test | Mammogen | Pre-clinical/Clinical Trial Preparation |
| Transpara Algorithm Enhancement | ScreenPoint Medical | Ongoing Development |
| AI-Powered Breast Imaging Algorithms | Hologic | Commercial Roll-out |